Genetically Engineered T-Cells + Vaccine for Metastatic Cancer
Trial Summary
What is the purpose of this trial?
Background: Many cancer cells produce substances called antigens that are unique to each cancer. These antigens stimulate the body s immune responses. One approach to treating these cancers is to take disease-fighting white blood cells from a person, change those cells so they will target the specific proteins (called antigens) from the cancer cells, and return them to that person s blood. The use of the white blood cells in this manner is one form of gene therapy. A vaccine may help these modified white cells work better. Objective: To test a cancer treatment that uses a person s own modified white blood cells along with a vaccine that targets a specific protein. Eligibility: Adults aged 18 to 72 years with certain solid tumors that have spread after treatment. Design: Participants will undergo leukapheresis: Blood is removed from the body through a tube attached to a needle inserted into a vein. The blood passes through a machine that separates out the white blood cells. The remaining blood is returned to the body through a second needle. Participants will stay in the hospital for 3 or 4 weeks. They will take chemotherapy drugs for 1 week to prepare for the treatment. Then their modified white cells will be infused through a needle in the arm. They will take other drugs to prevent infections after the infusion. The vaccine is injected into a muscle; participants will receive their first dose of the vaccine on the same day as their cell infusion. Participants will have follow-up visits 4, 8, and 12 weeks after the cell infusions. They will receive 2 or 3 additional doses of the boost vaccine during these visits. Follow-up will continue for 5 years, but participants will need to stay in touch with the gene therapy team for 15 years. ...
Do I need to stop my current medications for the trial?
The trial protocol does not specify if you need to stop taking your current medications. However, you must have completed any prior systemic therapy before enrolling.
What data supports the effectiveness of this treatment for metastatic cancer?
Is the genetically engineered T-cell and vaccine treatment for metastatic cancer safe for humans?
Research shows that genetically engineered T-cells, like those used in cancer treatments, have been developed with methods that maintain low toxicity and high cell viability. While there are concerns about potential side effects, strategies are being developed to improve safety, such as integrating failsafe switches to manage toxicities.12567
How is the treatment with genetically engineered T-cells and vaccine for metastatic cancer different from other treatments?
This treatment is unique because it uses T-cells that are genetically engineered to specifically target KRAS mutations, which are common in certain cancers. Unlike traditional treatments, this approach directly modifies the patient's own immune cells to enhance their ability to recognize and attack cancer cells, offering a personalized and potentially more effective therapy.12358
Eligibility Criteria
This trial is for adults aged 18-72 with certain advanced solid tumors like urogenital, gastrointestinal, ovarian, colorectal, non-small cell lung, and breast cancers that have spread despite treatment. Participants must be able to undergo leukapheresis and stay in the hospital for about a month.Inclusion Criteria
Exclusion Criteria
Trial Timeline
Screening
Participants are screened for eligibility to participate in the trial
Leukapheresis and Preparation
Participants undergo leukapheresis to collect white blood cells, followed by a chemotherapy regimen to prepare for treatment
Treatment
Participants receive genetically modified T-cells and a KRAS-targeted vaccine
Follow-up
Participants are monitored for safety and effectiveness after treatment
Long-term Follow-up
Participants maintain contact with the gene therapy team for extended monitoring
Treatment Details
Interventions
- Autologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations (CAR T-cell Therapy)
- Vaccine Directed Against KRAS Antigens (Cancer Vaccine)